MD Natascha Schill discusses the growing importance and commitment that Biogen has to Switzerland, including a USD one billion investment in new facilities and the creation of 400 jobs in the upcoming years; investing in the local workforce to support the company’s growth.
The headline-making news at the moment is Biogen's very recent decision to invest USD 1 billion in a next-generation manufacturing facility in Luterbach near Solothurn, which promises to triple the company's biologics production capacity. What made Switzerland, and more specifically the Canton of Solothurn, the obvious choice for such a sizeable investment?
We’re talking about a politically stable, business friendly and predictable country with a long tradition in pharmaceuticals development and strong track record on fostering innovation
